• Ernexa received a Nasdaq notice stating it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550(a)(2).
• Nasdaq staff said the company is not eligible for the typical 180-day compliance period because it completed a reverse stock split within the prior year.
• The company plans to request a hearing before the Nasdaq Hearing Panel, which would stay any suspension or delisting action while the hearing process is pending.
• The panel can grant an extension of up to 180 days from the notice date for the company to regain compliance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011922), on March 20, 2026, and is solely responsible for the information contained therein.